CCA
NTLA icon

Checchi Capital Advisers’s Intellia Therapeutics NTLA Stock Holding History

Checchi Capital Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,878
Closed -$304K – 539
2021
Q2 		$304K Sell
1,878
-637
-25% -$49.6K 0.03% 361
2021
Q1 		$202K Buy
+2,515
New +$169K 0.02% 486

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Checchi Capital Advisers's NTLA Position: Q3 2021 in Review

Checchi Capital Advisers sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 1,878 shares — an estimated $304K sold.

Checchi Capital Advisers first reported a position in NTLA in Q1 2021 and held it in 2 quarters. The position peaked at $304K in Q2 2021. 365 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Checchi Capital Advisers reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Checchi Capital Advisers sold 1,878 Intellia Therapeutics shares in Q3 2021, an estimated $304K.
  • Checchi Capital Advisers first reported a position in Intellia Therapeutics in Q1 2021 and held it in 2 quarters.
  • Checchi Capital Advisers's Intellia Therapeutics position peaked at $304K in Q2 2021.
  • 365 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Checchi Capital Advisers's 13F filing for Q3 2021, filed 9 Nov 2021.